Serum amyloid A (SAA) is an apo-lipoprotein produced by the liver in response to proinflammatory cytokines. Few data are available on SAA levels in patients with idiopathic pulmonary fibrosis (IPF), the most common idiopathic form of interstitial pneumonitis (ILD). This study compared SAA concentration in IPF patients to other ILD groups to explore its potential use as a clinical biomarker.
Vietri, L., D'Alessandro, M., Bergantini, L., Carleo, A., Cameli, P., Mazzei, M.A., et al. (2020). Specificity of serum amyloid A as a biomarker of idiopathic pulmonary fibrosis. INTERNAL MEDICINE JOURNAL, 50(12), 1571-1574 [10.1111/imj.15113].
Specificity of serum amyloid A as a biomarker of idiopathic pulmonary fibrosis
Vietri L.;d'Alessandro M.;Bergantini L.;Carleo A.;Cameli P.;Mazzei M. A.;Sestini P.;Bargagli E.
2020-01-01
Abstract
Serum amyloid A (SAA) is an apo-lipoprotein produced by the liver in response to proinflammatory cytokines. Few data are available on SAA levels in patients with idiopathic pulmonary fibrosis (IPF), the most common idiopathic form of interstitial pneumonitis (ILD). This study compared SAA concentration in IPF patients to other ILD groups to explore its potential use as a clinical biomarker.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/1128661
Attenzione
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo